The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of subsequent treatment after combination therapy in non-clear cell renal cell carcinoma (nccRCC).
 
Paulo Siqueira do Amaral
No Relationships to Disclose
 
Aniko Szabo
No Relationships to Disclose
 
Clara Hwang
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I)
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - Adcentrx (Inst); Astellas Pharma; AstraZeneca (Inst); Bayer (Inst); Exelixis (Inst); Fujifilm (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst); Scholar Rock (Inst); Seagen (Inst); Taiho Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Dendreon; Exelixis; Genentech; Merck
 
Pooja Ghatalia
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Merck (Inst)
 
Abhishek Tripathi
Consulting or Advisory Role - AADi; Bayer; Deka biosciences; Exelixis; Gilead Sciences; Pfizer; Seattle Genetics/Astellas
Speakers' Bureau - Sanofi
 
Hannah McManus
Consulting or Advisory Role - Astellas Pharma; Bayer; Pfizer
 
Hamid Emamekhoo
Consulting or Advisory Role - Bristol Myers Squibb company; Cardinal Health; Cardinal Health; Eisai; Janssen Biotech
 
Jennifer King
No Relationships to Disclose
 
Benjamin Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Lilly; Merck; Peloton Therapeutics; Pfizer; Sanofi; Telix Pharmaceuticals; Tempus; Xencor
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Yousef Zakharia
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; EMD Serono; Exelixis; Genzyme; Gilead Sciences; Janssen; Novartis; Pfizer
Research Funding - Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Newlink Genetics
 
Pedro Barata
Stock and Other Ownership Interests - Luminate Medical
Honoraria - UroToday
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Ipson; Merck; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Merck; Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Exelixis; Merck (Inst); Pfizer (Inst)
 
Arpita Desai
Honoraria - AVEO; OncLive/MJH Life Sciences; Targeted Oncology; Targeted Oncology
Consulting or Advisory Role - Aveo; Dendreon; Exelixis; Exelixis; Janssen; Janssen; Janssen Oncology; Merck
Research Funding - Exelixis (Inst); Merck
 
Melissa Reimers
Honoraria - Society of Urologic Nurses and Associates (SUNA)
Consulting or Advisory Role - Astellas Pharma; EMD Serono; Loxo; Pathos AI, Inc
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); ProfoundBio (Inst)
 
Yasser Ged
Consulting or Advisory Role - AVEO; BostonGene; Bristol Myers Squibb; Eisai; Exelixis; Targeted Oncology; Targeted Oncology
 
Elisabeth Heath
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Johnson & Johnson/Janssen; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Gilead Sciences; Novartis; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Calithera Biosciences (Inst); Caris Life Sciences (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo Inc. (Inst); Eisai (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); POINT Biopharma (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Sanofi
Other Relationship - Caris Centers of Excellence
 
Mehmet Bilen
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; SeaGen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Merck (Inst); Nektar (Inst); NiKang Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
James Brugarolas
Honoraria - Regeneron
Consulting or Advisory Role - Exelixis; Johnson & Johnson; Telix Pharmaceuticals
Patents, Royalties, Other Intellectual Property - U.S. Application Number: 17/153,128 “PET RADIOPHARMACEUTICALS FOR NON-INVASIVE EVALUATION OF HIF-2alpha” (Inst); U.S. Application Number: 17/206,895 “BIOMARKERS OF RESPONSE TO HIF-2alpha INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF” (Inst); U.S. Patent: US 11,576,889 B2 "METHODS OF IDENTIFYING AND TREATING PATIENTS WITH HIF-2 INHIBITOR RESISTANCE" (Inst)
 
Brian Rini
Leadership - MashupMD
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; HiberCell; Merck; Pfizer
Research Funding - ADC Therapeutics (Inst); Adela (Inst); Aravive (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Gilead Sciences (Inst); HiberCell (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Eisai
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Eisai; Exelixis; Janssen Oncology; Pfizer
Speakers' Bureau - Astellas Pharma; AVEO; Eisai; Exelixis; Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Exelixis; Janssen